In 2022, an estimated 11·7 million people were affected by chronic hepatitis C virus (HCV) infection in the WHO Eastern Mediterranean Region (EMR), accounting for 23% of the global burden.1 This ...

Let’s Break It Down,” emphasize the urgent need to remove barriers to prevention, testing, and treatment to reduce liver cancer and eliminate hepatitis by 2030.

Assembly Biosciences, Inc. (NASDAQ: ASMB) is one of the growth stocks that could double by 2027. On June 25, the company ...

In a pair of articles published in Lancet Gastroenterology & Hepatology, scientists lay out the case for why we should expand ...

A study just published on Eurosurveillance has found evidence of substantial lifetime exposure to hepatitis B and C viruses in Ukraine in a 2021 nationwide, representative sample of the population, ...

Discover a study comparing HBV- and alcohol-related ACLF, highlighting distinct clinical profiles and the need for aetiology-specific treatment strategies.

TherVacB, a therapeutic vaccine for chronic hepatitis B, has entered its first clinical trial in patients. The first patient was enrolled in June 2025 and treated with the vaccine. In a previous trial ...